Vedana is advancing a portfolio of internally discovered, long-acting, subcutaneously delivered antibody therapies designed to prevent migraine by targeting PACAP and combinatorial PACAP/CGRP biology. Its lead program is an anti-PACAP antibody and its second program is a bispecific antibody that targets both PACAP and CGRP. The company emphasizes highly potent, long half-life antibodies intended for self-injection at home. Vedana was founded and built by experienced migraine drug developers and industry leaders who worked on approved CGRP medicines and emerging PACAP approaches. The company launched from stealth and is based in Seattle. Vedana announced a $46 million Series A to fund advancement of its pipeline.

Total raised

$46M

Funding rounds

1

Latest round

Series A

Latest activity

Jun 2026